Hidehito Horinouchi, Assistant Chief of the National Cancer Center Hospital, shared a post on X:
“Oral: Lung / Thoracic Cancer 1
Chairs: Drs. Makoto Nishio, Nobuyuki Yamamoto.
1st Line ICI in KRASm.
Resistance to Alectinib.
MARIPOSA trial.
Zonbertinib / Beamion Lung-1.
Firmonertinib / Read FURTHER.”
